The dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin, which enhances the bioavailability of incretin hormones, improves both glucose tolerance and lipid metabolism in individuals with type 2 diabetes [5–7], thereby targeting both microvascular and macrovascular complications. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.